Macrocure (MCUR) Receiving Somewhat Favorable Media Coverage, Report Finds

Media stories about Macrocure (NASDAQ:MCUR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Macrocure earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.63490564327 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://ledgergazette.com/2017/10/10/macrocure-mcur-receiving-somewhat-favorable-media-coverage-report-finds.html.

About Macrocure

Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.

Insider Buying and Selling by Quarter for Macrocure (NASDAQ:MCUR)

Receive News & Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply